Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marc Isamu Uemura, Cara L. Haymaker, Ravi Murthy, Marihella James, Mark Cornfeld, Srinivas Chunduru, Sudhir Agrawal, Cassian Yee, Jennifer A. Wargo, Rodabe Navroze Amaria, Sapna Pradyuman Patel, Hussein Abdul-Hassan Tawbi, Isabella Claudia Glitza, Scott Eric Woodman, Wen-Jen Hwu, Michael A. Davies, Patrick Hwu, Willem W Overwijk, Chantale Bernatchez, Adi Diab
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2797555553